Skye Bioscience
SKYE
52 hedge funds and large institutions have $78.1M invested in Skye Bioscience in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 19 reducing their positions, and 15 closing their positions.
1,849% more call options, than puts
Call options by funds: $2.32M | Put options by funds: $119K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.7% less ownership
Funds ownership: 65.86% → 64.16% (-1.7%)
5% less funds holding
Funds holding: 55 → 52 (-3)
8% less capital invested
Capital invested by funds: $85.3M → $78.1M (-$7.13M)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
63% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$556K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$401K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$337K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$169K |
| 5 |
Two Sigma Investments
New York
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$874K |
| 2 |
FAM
Fred Alger Management
New York
|
-$842K |
| 3 |
BlackRock
New York
|
-$501K |
| 4 |
Millennium Management
New York
|
-$258K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$227K |
SKYE Hedge Fund Activity: Q3 2025 in Review
52 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q3 2025, worth a combined $78.1M — down 8.4% from $85.3M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SKYE and 12 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 7 added.
The largest buyer was Marshall Wace, adding an estimated $556K. The largest seller was 5AM Venture Management, cutting an estimated $874K.
- 52 institutional investors held Skye Bioscience (SKYE) as of Q3 2025, down from 55 in Q2 2025.
- Funds reported $78.1M of Skye Bioscience stock for Q3 2025, down 8.4% quarter-over-quarter.
- 12 funds opened new Skye Bioscience positions in Q3 2025 and 15 closed out, a net change of -3 holders.
- The largest Skye Bioscience buyer in Q3 2025 was Marshall Wace, an estimated $556K added.
- The largest Skye Bioscience seller in Q3 2025 was 5AM Venture Management, an estimated $874K sold.
Based on aggregated 13F filings for Q3 2025.